Modified CD19 CAR-T in Patients With Relapsed or Refractory CD19+ B-cell Malignancies

Summary

This study aims to evaluate the safety and tolerance of modified CD19 CAR T cells in treating refractory/relapsed B-cell malignancies. CAR-T cells will be investigated as a single agent both in relapsed/refractory B-cell acute lymphoblastic leukaemia (B-ALL) and up to 60% of patients with B-cell non-Hodgkin's lymphoma (NHL).

Timeline

Start

2021-03-17

Primary completion

2023-01-01

Completion

2024-01-01

Drugs

Indications